Brochure: Dynabeads manual and automated SARS-CoV-2 enrichment
Achieve intact SARS-CoV-2 virus enrichment products. You only need a centrifuge, and the intact virus is enriched in less than 3 hours with very little hands-on time.
List view / Grid view
Achieve intact SARS-CoV-2 virus enrichment products. You only need a centrifuge, and the intact virus is enriched in less than 3 hours with very little hands-on time.
Dr Ying Kai Chan discusses his latest research into how the delivery of AAV vectors for gene therapies can be made safer and more effective.
A novel machine learning method can explain how glycans stabilise proteins, aiding the discovery and design of protein-based drugs.
The extraction and isolation of RNA is essential in many downstream applications. Check out the basics of RNA isolation from Thermo Fisher.
KingFisher APEX is our newest instrument for automation workflows for high throughput DNA and RNA extraction. With precision handling and touch screen interface.
Researchers have shown antibodies induced by the Pfizer and Moderna vaccines are less effective at neutralising certain SARS-CoV-2 variants.
New podcast on SARS-CoV-2 molecular testing: From human sample analysis to Wastewater Surveillance.
RiboMinus Bacteria 2.0 Transcriptome Isolation Kits perform efficient transcriptome enrichment from total bacterial RNA. Improve your RNA extraction from bacteria today.
See our guide on DNA purification methods. From organic extraction through automated high-throughput runs, these research solutions make sample preparation easy.
Cannabidiol's (CBD) anti-inflammatory properties could be harnessed to treat or prevent COVID-19, according to a new study.
A team has discovered how enzymes control the formation of bioactive rubromycin-polyketides, which could be used to bioengineer new compounds.
4 March 2021 | By Eurofins Discovery
Book your place for our free webinar and learn about how targeted protein degradation (TPD) utilises small molecules to hijack the cellular degradation machinery through the recruitment of E3 ubiquitin ligases to proteins of interest.
A team has created a biosynthetic pathway for E. coli that allows the bacteria to produce a common arthritis drug.
1 March 2021 | By Bruker Scientific, LLC
Watch our free on-demand webinar that focuses on the detailed description of the workflow and case studies of BAMS™ assays developed for targets relevant to neurology and virology.
26 February 2021 | By Domain Therapeutics
Watch our on-demand webinar which focused on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.